Products
Online Inquiry
Our Products Cannot Be Used As Medicines Directly For Personal Use.
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
AT-406
Cat No.
CEI-0179
Description
AT-406(SM-406) can inhibit XIAP, cIAP1, and cIAP2 proteins with Ki of 66.4, 1.9, and 5.1 nM.
CAS No.
1071992-99-8
Molecular Weight
561.71
Purity
>99%
Storage
2 years at -20 centigrade
Targets
XIAP, cIAP1, cIAP2
Molecular Formula
C32H43N5O4
Chemical Name
(5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxo-decahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide
Solubility
DSMO 112 mg/mL Water
In vitro
AT-406(SM-406) is a novel, potent and orally bioavailable Smac mimetic and an antagonist of the inhibitor of apoptosis proteins (IAPs). AT-406(SM-406) can inhibit XIAP, cIAP1, and cIAP2 proteins with Ki of 66.4, 1.9, and 5.1 nM. AT-406(SM-406) can induces rapid degradation of cellular cIAP1 protein, and inhibits cancer cell growth in various human cancer cell lines. In ovarian cancer cells, AT-406(SM-406) shows therapeutic efficacy and mechanism of action in 60% of human ovarian cancer cell lines. AT-406 induced apoptosis is correlated with its ability to down-regulate XIAP whereas AT-406 induces cIAP1 degradation in both AT-406 sensitive and resistance cell lines.
In vivo
In vivo, AT-406(SM-406) inhibits ovarian cancer progression and shows therapeutic potential for patients with inherent or acquired platinum resistance.In the combination with carboplatin, AT-406(SM-406) shows therapeutic efficacy.In vivo, AT-406(SM-406) enhances the carboplatin-induced ovarian cancer cell death and increases survival of the experimental mice by making ovarian cancer cells more sensitive to carboplatin.
Download
Download Datasheet